ES3036152T3 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation

Info

Publication number
ES3036152T3
ES3036152T3 ES19190372T ES19190372T ES3036152T3 ES 3036152 T3 ES3036152 T3 ES 3036152T3 ES 19190372 T ES19190372 T ES 19190372T ES 19190372 T ES19190372 T ES 19190372T ES 3036152 T3 ES3036152 T3 ES 3036152T3
Authority
ES
Spain
Prior art keywords
hcg
sialylation
mol
rhcg
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19190372T
Other languages
English (en)
Spanish (es)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of ES3036152T3 publication Critical patent/ES3036152T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES19190372T 2009-10-05 2010-10-04 Pharmaceutical preparation Active ES3036152T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
ES3036152T3 true ES3036152T3 (en) 2025-09-15

Family

ID=41471027

Family Applications (2)

Application Number Title Priority Date Filing Date
ES19190372T Active ES3036152T3 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation
ES10763000T Active ES2798258T3 (es) 2009-10-05 2010-10-04 Preparación farmacéutica que comprende HCG recombinante

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10763000T Active ES2798258T3 (es) 2009-10-05 2010-10-04 Preparación farmacéutica que comprende HCG recombinante

Country Status (25)

Country Link
US (5) US8975226B2 (Sortimente)
EP (2) EP3611185B1 (Sortimente)
JP (6) JP6176924B2 (Sortimente)
KR (7) KR20210014767A (Sortimente)
CN (1) CN107050434B (Sortimente)
AR (2) AR079876A1 (Sortimente)
AU (1) AU2010304922B2 (Sortimente)
BR (1) BR112012007990A2 (Sortimente)
CA (1) CA2776790A1 (Sortimente)
DK (1) DK2486051T3 (Sortimente)
ES (2) ES3036152T3 (Sortimente)
HR (1) HRP20200941T1 (Sortimente)
HU (1) HUE050793T2 (Sortimente)
IL (3) IL218548A (Sortimente)
IN (1) IN2012DN02073A (Sortimente)
JO (1) JOP20200039A1 (Sortimente)
LT (1) LT2486051T (Sortimente)
MX (1) MX2012003951A (Sortimente)
PL (1) PL2486051T3 (Sortimente)
PT (1) PT2486051T (Sortimente)
RS (1) RS60413B1 (Sortimente)
RU (2) RU2724528C2 (Sortimente)
SI (1) SI2486051T1 (Sortimente)
TW (2) TWI604850B (Sortimente)
WO (1) WO2011042688A1 (Sortimente)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) * 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN108646019B (zh) 2012-12-10 2021-06-25 生化学工业株式会社 新重组因子c、其制造方法、及内毒素的测定法
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
MX389908B (es) 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
EP3313859B1 (en) 2015-06-26 2019-11-20 Ferring BV Methods of purification and/or viral inactivation
EP3787667B1 (en) * 2018-04-30 2025-03-26 Ferring B.V. Composition for controlled ovarian stimulation
EP4100425A1 (en) * 2020-02-05 2022-12-14 Novartis AG Cho cell expressing il-15 heterodimers
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
UA61053C2 (en) * 1995-03-21 2003-11-17 Applied Research Systems Stable liquid pharmaceutical compositions, method for its production and delivery form
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN100404551C (zh) 1997-06-25 2008-07-23 雪兰诺实验室有限公司 二硫键交联的糖蛋白激素类似物及其制备和应用
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
EP1176976B2 (en) * 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
MXPA02007871A (es) 2000-02-22 2003-02-10 Applied Research Systems Proceso para la purificacion de gonadotropina corionica humana (hcg) y gonadotropina corionica humana recombinante purificada mediante este proceso.
PL369098A1 (en) 2001-09-12 2005-04-18 Applied Research Systems Ars Holding N.V. Use of hcg in controlled ovarian hyperstimulation
EP1621549A3 (en) * 2001-10-22 2006-03-01 Applied Research Systems ARS Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicinaments
BR0213402A (pt) 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
AU2004226353A1 (en) * 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
EP2055189A1 (en) * 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
EP1654353B1 (en) * 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
DK1711834T3 (da) 2004-02-04 2010-11-29 Centre Nat Rech Scient Fremgangsmåde til screening af glycoform-specifikke antistoffer
CN1926242B (zh) * 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP1861124A2 (en) * 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch
JP2009504985A (ja) 2005-08-15 2009-02-05 シーメンス ヴィディーオー オートモーティヴ コーポレイション ディーゼル車排気への炭化水素計量弁
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US9187532B2 (en) * 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) * 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA2831486A1 (en) * 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
JP2020000246A (ja) 2020-01-09
CN102549011A (zh) 2012-07-04
US8975226B2 (en) 2015-03-10
RU2724528C2 (ru) 2020-06-23
KR20190028823A (ko) 2019-03-19
EP3611185A1 (en) 2020-02-19
RU2016118236A (ru) 2018-10-29
US20140249082A1 (en) 2014-09-04
TWI532495B (zh) 2016-05-11
US9676835B2 (en) 2017-06-13
US11292824B2 (en) 2022-04-05
KR20170133531A (ko) 2017-12-05
KR102213154B1 (ko) 2021-02-05
JP2013506708A (ja) 2013-02-28
IL218548A0 (en) 2012-05-31
CN107050434B (zh) 2021-07-27
IN2012DN02073A (Sortimente) 2015-08-21
RU2012112907A (ru) 2013-11-10
JP6580104B2 (ja) 2019-09-25
US20180030107A1 (en) 2018-02-01
ES2798258T3 (es) 2020-12-10
CA2776790A1 (en) 2011-04-14
JP7292153B2 (ja) 2023-06-16
HUE050793T2 (hu) 2021-01-28
US12234272B2 (en) 2025-02-25
PL2486051T3 (pl) 2020-09-07
KR101987982B1 (ko) 2019-06-11
US10526390B2 (en) 2020-01-07
EP3611185B1 (en) 2025-04-30
JP6176924B2 (ja) 2017-08-09
KR102489143B1 (ko) 2023-01-13
JOP20200039A1 (ar) 2022-10-30
US20220340634A1 (en) 2022-10-27
BR112012007990A2 (pt) 2017-07-25
IL250733B (en) 2019-07-31
IL250733A0 (en) 2017-04-30
TW201113030A (en) 2011-04-16
RU2016118236A3 (Sortimente) 2019-09-18
JP2021176867A (ja) 2021-11-11
IL218548A (en) 2017-03-30
RS60413B1 (sr) 2020-07-31
PT2486051T (pt) 2020-06-17
AR079876A1 (es) 2012-02-29
IL267556A (en) 2019-08-29
KR20210014767A (ko) 2021-02-09
CN107050434A (zh) 2017-08-18
RU2588650C2 (ru) 2016-07-10
AU2010304922A1 (en) 2012-03-29
EP2486051A1 (en) 2012-08-15
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
HRP20200941T1 (hr) 2020-09-18
KR20210141771A (ko) 2021-11-23
US20130023476A1 (en) 2013-01-24
JP2023075144A (ja) 2023-05-30
US20200247863A1 (en) 2020-08-06
KR20230012104A (ko) 2023-01-25
LT2486051T (lt) 2020-07-10
KR20190067256A (ko) 2019-06-14
KR101804479B1 (ko) 2017-12-05
SI2486051T1 (sl) 2020-08-31
TW201632198A (zh) 2016-09-16
JP2018076296A (ja) 2018-05-17
EP2486051B1 (en) 2020-03-25
WO2011042688A1 (en) 2011-04-14
MX2012003951A (es) 2012-05-29
JP2016074680A (ja) 2016-05-12
DK2486051T3 (da) 2020-06-22
AU2010304922B2 (en) 2014-11-06
JP7196244B2 (ja) 2022-12-26
JP6310440B2 (ja) 2018-04-11
AR125991A2 (es) 2023-08-30

Similar Documents

Publication Publication Date Title
ES3036152T3 (en) Pharmaceutical preparation
ES2989729T3 (es) FSH recombinante que incluye sialilación en alfa 2,3 y alfa 2,6
ES2693273T3 (es) Preparación farmacéutica
CN102549011B (zh) 包含重组hcg的药物制剂
HK40020346A (en) Pharmaceutical preparation
Class et al. Patent application title: Pharmaceutical Preparation Comprising Recombinant HcG Inventors: Ian Cottingham (St. Prex, CH) Daniel Plaksin (St. Prex, CH) Richard Boyd White (San Diego, CA, US) Assignees: Ferring BV
HK1174338B (en) Pharmaceutical preparation comprising recombinant hcg
HK1174338A (en) Pharmaceutical preparation comprising recombinant hcg